Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

Springer Science and Business Media LLC - Tập 16 - Trang 1-4 - 2023
Juanjuan Zhao1, Quan Ren1, Xinyuan Liu2, Xiangqian Guo2, Yongping Song1
1Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, China

Tóm tắt

Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 16

1-4

Thông tin tác giả